BOSTON, November 16, 2026
Biomapas, a leading integrated life sciences services provider, today announced its entry into the US market with the acquisition of the Chemistry, Manufacturing and Controls (CMC) business of Alira Health. The Boston-based team, which provides integrated CMC solutions to preclinical- and clinical-stage biopharma companies, will form the foundation of Biomapas North America, the group’s new US business.
The move supports Biomapas’ strategy to become a leading integrated, digitally enabled global partner for lifecycle management and product development, growing both organically and through acquisitions. The US is the largest market for Biomapas’ clients, and building a presence there is central to that strategy.
The acquisition adds a specialist CMC service line to Biomapas’ regulatory affairs, pharmacovigilance and product, clinical development and digital & consulting services. The team of more than 35 experienced CMC experts, many with senior industry backgrounds, provides clients with the diverse technical expertise required to ensure successful outsourced clinical manufacturing, as well as quality assurance oversight, CMC regulatory strategy and filings, and project management. The CMC team has deep experience developing complex biologics, including monoclonal antibodies, ADCs, oligonucleotides, CAR-T and other cell therapies, as well as small molecules and peptides.
The CMC team has a strong reputation among North American biopharma sponsors and has helped more than 90 clients across the US and Europe bring their products into clinical development and to market. Clients will continue to work with the same team and contacts, ensuring continuity of service. Over time, Biomapas North America will also serve as the platform to bring the group’s wider service offering to US sponsors.
Sean Forestell, Senior Vice President, CMC Operations, Biomapas: “Joining Biomapas is the right next step for our team and our clients. Biomapas gives us a broader platform to take our CMC expertise to more sponsors, in the US and beyond. For our clients, it means access to regulatory, safety, clinical and digital support from one partner as their products move through development. We share a commitment to quality and close client relationships, and we look forward to building on that together.”
Xavier Duburcq, CEO of Biomapas, said: “Establishing Biomapas North America is an important milestone for the group. The US is our clients’ largest market, and the Alira Health CMC team gives us a solid base there, with strong relationships among biotech sponsors.
“CMC is a high-value, regulatory-driven area that sits upstream of our existing services, and the team brings specialist expertise, particularly in complex biologics. Together with our regulatory, safety and clinical teams, this lets us support clients earlier in development and across more of the product lifecycle.“
Carbyne Equity Partners, majority shareholder of Biomapas, has backed the company since October 2024 to build a global, integrated life sciences services platform. The acquisition of Alira Health’s CMC business follows those of Delta PV in 2025 and Pinnaxis in 2026, adding a North American presence and a dedicated CMC capability to the group.
About Biomapas
Biomapas is an integrated life sciences services provider supporting pharmaceutical, biotechnology and medical device companies across the product lifecycle. The company delivers regulatory affairs, pharmacovigilance, quality assurance, medical information, clinical research and digital & consulting services, combining global standards with local expertise and technology-driven efficiency. Biomapas has offices in Luxembourg, Lithuania, Georgia, Turkey and India, a US presence through Biomapas North America, and teams in more than 30 countries.
For more information, please visit www.biomapas.com
About Carbyne Equity Partners
Carbyne Equity Partners is a private equity firm investing in growing European businesses with strong market positions and a commitment to innovation. Its focus spans healthcare, nutrition and agricultural inputs, sectors where the firm leverages its extensive network of entrepreneurial investors. Working closely with management teams, Carbyne supports businesses in accelerating growth and strengthening long-term market leadership.
For more information, please visit www.carbynepartners.de
Xavier Duburcq, PhD
CEO, Biomapas
Sean Forestell, PhD
Senior VP, CMC

